ICOS Pafase
Executive Summary
Development of Pafase (rPAF-AH) as a prophylactic for patients undergoing endoscopic retrograde cholangiopancreatography discontinued following Phase II results showing no statistically significant effect compared to placebo in preventing acute pancreatitis and the need for hospitalization. Results of Phase II trial of Pafase for acute respiratory distress syndrome are expected in the second quarter 2000